Henry R Kranzler
Overview
Explore the profile of Henry R Kranzler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
509
Citations
15199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farokhnia M, Tazare J, Pince C, Bruns Vi N, Gray J, Lo Re Iii V, et al.
J Clin Invest
. 2025 Mar;
PMID: 40048376
Background: Despite growing preclinical evidence that glucagon-like peptide-1 receptor agonists (GLP-1RAs) could be repurposed to treat alcohol use disorder (AUD), clinical evidence is scarce. Additionally, the potential impact of dipeptidyl...
2.
Wang L, Kranzler H, Gelernter J, Zhou H
Biol Psychiatry
. 2025 Feb;
PMID: 39892688
Background: Alcohol use disorder (AUD) is a leading cause of death and disability worldwide. There has been substantial progress in identifying genetic variants underlying AUD. However, whole-exome sequencing (WES) studies...
3.
Liang C, Luo C, Kranzler H, Bian J, Chen Y
J Am Med Inform Assoc
. 2025 Jan;
PMID: 39864407
Objective: To develop a distributed algorithm to fit multi-center Cox regression models with time-varying coefficients to facilitate privacy-preserving data integration across multiple health systems. Materials And Methods: The Cox model...
4.
Dubroff J, Hsieh C, Wiers C, Lee H, Li E, Schubert E, et al.
medRxiv
. 2025 Jan;
PMID: 39802787
Introduction: Mu-opioid receptors (MORs) are G-coupled protein receptors with a high affinity for both endogenous and exogenous opioids. MORs are widely expressed in the central nervous system (CNS), peripheral organs,...
5.
Chakravorty S, Morales K, Perlis M, Kuna S, He S, Oslin D, et al.
medRxiv
. 2025 Jan;
PMID: 39802757
Study Objectives: 1) To determine the efficacy of Cognitive Behavioral Therapy for Insomnia (CBT-I) for improving insomnia, alcohol-related outcomes, and daytime functioning at post-treatment and at 3- and 6-month follow-up,...
6.
Davis C, Jinwala Z, Hatoum A, Toikumo S, Agrawal A, Rentsch C, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2453913.
PMID: 39786773
Importance: Recently, the US Food and Drug Administration gave premarketing approval to an algorithm based on its purported ability to identify individuals at genetic risk for opioid use disorder (OUD)....
7.
Kranzler H, Stone A, Schichman S, Griffin L, Roggenkamp H, Thase M, et al.
Psychopharmacol Bull
. 2025 Jan;
55(1):8-25.
PMID: 39744412
Background: Immunologic measures have been studied as predictors of who will respond to standard antidepressants. Two previous, small studies of pretreatment leukocyte mRNA expression levels of the cytokines macrophage migration...
8.
Harris R, Kearney M, Keddem S, Calderbank T, Tomczuk L, Clapp J, et al.
Addict Sci Clin Pract
. 2024 Dec;
19(1):96.
PMID: 39702538
No abstract available.
9.
Linner R, Mallard T, Barr P, Sanchez-Roige S, Madole J, Driver M, et al.
Nat Neurosci
. 2024 Dec;
28(1):213.
PMID: 39643700
No abstract available.
10.
Sullivan K, Kainer D, Lane M, Cashman M, Miller J, Garvin M, et al.
Biol Psychiatry
. 2024 Nov;
PMID: 39615775
Background: Opioid addiction is a worldwide public health crisis. In the United States, for example, opioids cause more drug overdose deaths than any other substance. However, opioid addiction treatments have...